Treatment with BCR inhibitors increases ROR1 expression in CLL cells

KOTAŠKOVÁ, Jana, Šárka PAVLOVÁ, Karla PLEVOVÁ, Jitka MALČÍKOVÁ, Olga STEHLÍKOVÁ, Lucie POPPOVÁ, Helena OLBERTOVÁ, Michael DOUBEK, Vítězslav BRYJA and Šárka POSPÍŠILOVÁ. Treatment with BCR inhibitors increases ROR1 expression in CLL cells. In 22nd EHA Annual Congress; Madrid, Spain, červen 2017 in Haematologica (2017). 2017.

Basic information

• Original name: Treatment with BCR inhibitors increases ROR1 expression in CLL cells
• Authors: KOTAŠKOVÁ, Jana (203 Czech Republic, belonging to the institution), Šárka PAVLOVÁ (203 Czech Republic, belonging to the institution), Karla PLEVOVÁ (203 Czech Republic, belonging to the institution), Jitka MALČÍKOVÁ (203 Czech Republic, belonging to the institution), Olga STEHLÍKOVÁ (203 Czech Republic, belonging to the institution), Lucie POPPOVÁ (203 Czech Republic, belonging to the institution), Helena OLBERTOVÁ (203 Czech Republic, belonging to the institution), Michael DOUBEK (203 Czech Republic, belonging to the institution), Vítězslav BRYJA (203 Czech Republic, belonging to the institution) and Šárka POSPÍŠILOVÁ (203 Czech Republic, belonging to the institution).
• Edition: 22nd EHA Annual Congress; Madrid, Spain, červen 2017 in Haematologica (2017), 2017.

Other information

• Original language: English
• Type of outcome: Conference abstract
• Field of Study: 30205 Hematology
• Confidentiality degree: is not subject to a state or trade secret
• RIV identification code: RIV/00216224:14740/17:00095696
• Organization unit: Central European Institute of Technology
• UT WoS: 000404127003146
• Keywords in English: BCR; CLL; ROR1
• Tags: rivok

Abstract

Treatment with BCR inhibitors increases ROR1 expression in CLL cells, Treatment with BCR inhibitors increases ROR1 expression in CLL cells

Links

• LQ1601, research and development project: Name: CEITEC 2020 (Acronym: CEITEC2020)

Investor: Ministry of Education, Youth and Sports of the CR

• MUNI/A/1106/2016, interní kód MU: Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit IV (Acronym: VýDiTeHeMA IV)

Investor: Masaryk University, Category A

• NV15-29793A, research and development project: Name: Analýza Wnt/PCP jako nástroj pro lepší management chronické lymfocytární leukémie
• NV15-31834A, research and development project: Name: Vliv selekce genomických poškození na průběh chronické lymfocytární leukémie
• 15-30015A, interní kód MU(CEP code: NV15-30015A): Name: Analýza klonální heterogenity chronické lymfocytární leukemie pomoci sekvenování nové generace genu pro B-buněčný receptor. Národní studie

Investor: Ministry of Health of the CR